Payment overview · 2025
General Payments
$5,435.04
96 reported records · 13 companies
Healthcare provider profile · identity verified
David Michael Campsey, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · MORGANTOWN, WV · NPI 1467417048
Verified facts
What the public records show
CMS Open Payments records show David Michael Campsey, MD received $5,435.04 in general payments during 2025 across 96 reported records.
Abbott Laboratories accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,744.86 | 32.1% | 31 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $1,402.40 | 25.8% | 11 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$767.92 | 14.1% | 20 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $298.68 | 5.5% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $288.29 | 5.3% | 22 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $231.31 | 4.3% | 2 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $155.68 | 2.9% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $151.86 | 2.8% | 1 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $146.31 | 2.7% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $121.08 | 2.2% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $66.94 | 1.2% | 1 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $52.13 | 1.0% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $7.58 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,884.00 | 91 |
| Travel and Lodging | $1,551.04 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $1,663.68 | 26 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $669.75 | 15 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $231.31 | 2 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $203.31 | 17 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $183.48 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $183.48 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $171.83 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $151.86 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $146.31 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $146.31 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $121.08 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $121.08 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $102.88 | 2 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $99.05 | 1 | 2025 |
Source payment records
|
|||||
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $66.94 | 1 | 2025 |
Source payment records
|
|||||
| Pounce LP Thrombectomy Normalized: pounce lp thrombectomy |
Device | Surmodics, Inc. | $52.13 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $52.13 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $52.13 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $52.13 | 1 | 2025 |
Source payment records
|
|||||
| Pounce XL Thrombectomy Normalized: pounce xl thrombectomy |
Device | Surmodics, Inc. | $52.13 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $49.25 | 1 | 2025 |
Source payment records
|
|||||
| Rotablator Rotational Atherectomy System Console Kit Normalized: rotablator rotational atherectomy system console kit |
Device | Boston Scientific Corporation | $48.41 | 3 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $36.57 | 2 | 2025 |
Source payment records
|
|||||
| CLOSUREFAST Normalized: closurefast |
Device | Medtronic, Inc. | $28.01 | 2 | 2025 |
Source payment records
|
|||||
| CONFIRM RX Normalized: confirm rx |
Device | Abbott Laboratories | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $23.55 | 2 | 2025 |
Source payment records
|
|||||
| AMPLATZER TALISMAN Normalized: amplatzer talisman |
Device | Abbott Laboratories | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| PULSESELECT Normalized: pulseselect |
Device | Medtronic, Inc. | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $9.80 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $7.58 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $2.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 320 | 116 |
| Atorvastatin Calcium | Atorvastatin Calcium | 198 | 74 |
| Eliquis | Apixaban | 152 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 50 |
| Losartan Potassium | Losartan Potassium | 127 | 50 |
| Lisinopril | Lisinopril | 122 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 104 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 84 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 18 |
| Carvedilol | Carvedilol | 57 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 27 |
| Furosemide | Furosemide | 51 | 23 |
| Ezetimibe | Ezetimibe | 36 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 14 |
| Simvastatin | Simvastatin | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | 11 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 16 |
| Brilinta | Ticagrelor | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,435.04 · 96 records | Abbott Laboratories | AMPLATZER AMULET, AMPLATZER TALISMAN, ANGIOVAC, ARTIX MT, AVEIR, AVVIGO Guidance System, CLOSUREFAST, CLOTTRIEVER BOLD CATHETER, CONFIRM RX, COREVALVE EVOLUT R, CT THROMBECTOMY SYSTEM KIT, ENDOCROSS Device, FFRct, FLOWTRIEVER CATHETER, S, Flexitouch Plus, GALLANT, Indigo System, LifeVest, MICRA, Nimbl, PULSESELECT, Pounce LP Thrombectomy, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, Pounce XL Thrombectomy, Rotablator Rotational Atherectomy System Console Kit, SAPIEN 3 Ultra RESILIA, SYMPLICITY G3, Torus Stent Graft System, Varithena Administration Pack | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error